Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of “Moderate Buy” from Analysts

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has been given an average rating of “Moderate Buy” by the five ratings firms that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $11.75.

VRCA has been the subject of several analyst reports. Needham & Company LLC restated a “hold” rating and issued a $12.00 target price on shares of Verrica Pharmaceuticals in a research note on Thursday, October 3rd. Royal Bank of Canada dropped their price target on shares of Verrica Pharmaceuticals from $13.00 to $11.00 and set an “outperform” rating for the company in a research report on Friday, October 4th. TD Cowen decreased their target price on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Monday. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 2nd.

Hedge Funds Weigh In On Verrica Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Simplify Asset Management Inc. acquired a new position in Verrica Pharmaceuticals in the 2nd quarter valued at about $2,041,000. Vanguard Group Inc. grew its holdings in shares of Verrica Pharmaceuticals by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock valued at $7,511,000 after purchasing an additional 7,609 shares in the last quarter. Quest Partners LLC purchased a new stake in Verrica Pharmaceuticals during the 2nd quarter worth approximately $50,000. Key Financial Inc acquired a new position in shares of Verrica Pharmaceuticals in the second quarter worth $69,000. Finally, Renaissance Technologies LLC purchased a new position in Verrica Pharmaceuticals in the second quarter valued at $332,000. 42.45% of the stock is currently owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Stock Down 2.2 %

Verrica Pharmaceuticals stock traded down $0.04 during mid-day trading on Monday, reaching $1.57. The stock had a trading volume of 262,524 shares, compared to its average volume of 436,819. The firm has a market capitalization of $66.39 million, a PE ratio of -0.90 and a beta of 1.45. The stock’s 50-day simple moving average is $2.09 and its 200-day simple moving average is $5.63. The company has a debt-to-equity ratio of 29.58, a quick ratio of 2.23 and a current ratio of 2.36. Verrica Pharmaceuticals has a fifty-two week low of $1.04 and a fifty-two week high of $11.41.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The business had revenue of $5.18 million during the quarter, compared to the consensus estimate of $4.70 million. On average, sell-side analysts forecast that Verrica Pharmaceuticals will post -1.58 EPS for the current fiscal year.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.